ATE277906T1 - 4-carboxamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp inhibitoren - Google Patents
4-carboxamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp inhibitorenInfo
- Publication number
- ATE277906T1 ATE277906T1 AT99940421T AT99940421T ATE277906T1 AT E277906 T1 ATE277906 T1 AT E277906T1 AT 99940421 T AT99940421 T AT 99940421T AT 99940421 T AT99940421 T AT 99940421T AT E277906 T1 ATE277906 T1 AT E277906T1
- Authority
- AT
- Austria
- Prior art keywords
- tetrahydrochinolines
- carboxamino
- methyl
- cetp inhibitors
- cetp
- Prior art date
Links
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10092998P | 1998-09-17 | 1998-09-17 | |
| PCT/IB1999/001529 WO2000017166A1 (en) | 1998-09-17 | 1999-09-10 | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE277906T1 true ATE277906T1 (de) | 2004-10-15 |
Family
ID=22282259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99940421T ATE277906T1 (de) | 1998-09-17 | 1999-09-10 | 4-carboxamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp inhibitoren |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6147090A (de) |
| EP (1) | EP1114033B1 (de) |
| JP (1) | JP3655193B2 (de) |
| AR (1) | AR021482A1 (de) |
| AT (1) | ATE277906T1 (de) |
| AU (1) | AU5439899A (de) |
| BR (1) | BR9913842A (de) |
| CA (1) | CA2344556A1 (de) |
| CO (1) | CO5150220A1 (de) |
| DE (1) | DE69920727T2 (de) |
| DK (1) | DK1114033T3 (de) |
| DZ (1) | DZ2889A1 (de) |
| ES (1) | ES2228086T3 (de) |
| GT (1) | GT199900149A (de) |
| HN (1) | HN1999000155A (de) |
| MA (1) | MA26687A1 (de) |
| MY (1) | MY121838A (de) |
| PA (1) | PA8481501A1 (de) |
| PE (1) | PE20001048A1 (de) |
| PT (1) | PT1114033E (de) |
| SI (1) | SI1114033T1 (de) |
| SV (1) | SV1999000149A (de) |
| TN (1) | TNSN99172A1 (de) |
| TW (1) | TWI232859B (de) |
| WO (1) | WO2000017166A1 (de) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| CA2406574C (en) * | 2000-04-10 | 2006-12-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| EP1911462A3 (de) | 2001-01-26 | 2011-11-30 | Schering Corporation | Zusammensetzungen enthaltend einen Sterolabsorptionshemmer |
| IL156445A0 (en) | 2001-01-26 | 2004-01-04 | Schering Corp | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| KR20070120617A (ko) | 2001-01-26 | 2007-12-24 | 쉐링 코포레이션 | 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물 |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| WO2002078625A2 (en) * | 2001-03-28 | 2002-10-10 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
| SE0101161D0 (sv) | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
| OA12619A (en) * | 2001-06-21 | 2006-06-12 | Pfizer Prod Inc | Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors. |
| EP1269994A3 (de) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten |
| KR100759635B1 (ko) * | 2001-06-22 | 2007-09-17 | 화이자 프로덕츠 인코포레이티드 | 비정질 약물의 흡착체의 약학 조성물 |
| MXPA03011784A (es) | 2001-06-22 | 2004-04-02 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros. |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| EP1429756B1 (de) | 2001-09-21 | 2006-11-22 | Schering Corporation | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
| CN1596240A (zh) * | 2001-12-19 | 2005-03-16 | 阿特罗吉尼克斯公司 | 查耳酮衍生物及其治疗疾病的用途 |
| WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| DE60320940D1 (de) * | 2002-02-01 | 2008-06-26 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| BR0307332A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US7332514B2 (en) | 2002-08-30 | 2008-02-19 | Japan Tobacco Inc. | Dibenzylamine compound and medicinal use thereof |
| PL376156A1 (en) | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US20090181966A1 (en) * | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| AU2003269327A1 (en) * | 2002-10-21 | 2004-05-04 | Warner-Lambert Company Llc | Tetrahydroquinoline derivatives as crth2 antagonists |
| CA2504916A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| WO2004056727A2 (en) * | 2002-12-19 | 2004-07-08 | Atherogenics, Inc. | Process of making chalcone derivatives |
| AU2003283769A1 (en) | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| WO2004081004A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| WO2004081002A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| DE602004018617D1 (de) | 2003-03-07 | 2009-02-05 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
| KR20080008440A (ko) * | 2003-03-17 | 2008-01-23 | 니뽄 다바코 산교 가부시키가이샤 | Ｃｅｔｐ 억제제의 약제학적 조성물 |
| BRPI0408442A (pt) * | 2003-03-17 | 2006-04-04 | Japan Tobacco Inc | método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato |
| US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| SG141430A1 (en) * | 2003-05-30 | 2008-04-28 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
| JP2007501218A (ja) * | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物 |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| US7317025B2 (en) | 2003-09-24 | 2008-01-08 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Non-peptidic NPY Y2 receptor inhibitors |
| KR20070087197A (ko) | 2003-09-26 | 2007-08-27 | 니뽄 다바코 산교 가부시키가이샤 | 잔여 리포프로테인 생산 저해 방법 |
| WO2005037796A1 (en) * | 2003-10-08 | 2005-04-28 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| EP1918000A2 (de) | 2003-11-05 | 2008-05-07 | Schering Corporation | Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände |
| BRPI0508966A (pt) | 2004-03-26 | 2007-08-21 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| MY139887A (en) * | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| US20060063828A1 (en) * | 2004-06-28 | 2006-03-23 | Weingarten M D | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
| EP1807070A1 (de) * | 2004-09-29 | 2007-07-18 | Schering Corporation | Kombinationen aus substituierten azetidinonen und cb1-antagonisten |
| US7700597B2 (en) | 2004-12-03 | 2010-04-20 | Schering Corporation | Substituted piperazines as CB1 antagonists |
| US7700774B2 (en) * | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
| EP1844078B1 (de) | 2005-02-03 | 2016-09-28 | Bend Research, Inc | Pharmazeutische zusammensetzungen mit erhöhter leistung |
| BRPI0608553A2 (pt) | 2005-02-24 | 2010-01-12 | Millennium Pharm Inc | antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias |
| WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| BRPI0618379A2 (pt) | 2005-11-08 | 2011-08-30 | Ranbaxy Lab Ltd | processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico |
| WO2007084450A2 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
| UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| JP4870171B2 (ja) * | 2006-02-07 | 2012-02-08 | エフ．ホフマン−ラ ロシュ アーゲー | ベンズアミドおよびヘテロアレーン誘導体 |
| AR059838A1 (es) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
| WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| AU2007274724B2 (en) * | 2006-07-14 | 2012-07-26 | Ranbaxy Laboratories Limited | Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| CA2683534C (en) | 2007-04-13 | 2015-02-24 | Kowa Company, Ltd. | Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same |
| WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| CN101790521A (zh) * | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| WO2009005646A2 (en) | 2007-06-28 | 2009-01-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| CA2703203C (en) | 2007-10-22 | 2015-12-15 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| CA2724426A1 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| MX2011000664A (es) | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| EP2382204B1 (de) | 2008-12-23 | 2018-07-11 | Merck Sharp & Dohme Corp. | Pyrimidinderivate als gpcr-modulatoren zur verwendung bei der behandlung von obesitas und diabetes |
| AU2009330208A1 (en) | 2008-12-23 | 2011-08-04 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| EP2414348B1 (de) | 2009-04-03 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclische piperidin- und piperazinderivate als gpcr-modulatoren zur behandlung von obesitas, diabetes und anderen stoffwechselkrankheiten |
| AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
| CA2778684A1 (en) | 2009-10-29 | 2011-05-05 | Schering Corporation | Bridged bicyclic piperidine derivatives and methods of use thereof |
| US8912206B2 (en) | 2009-11-23 | 2014-12-16 | Merck Sharp & Dohme Corp. | Pyrimidine ether derivatives and methods of use thereof |
| WO2011062885A1 (en) | 2009-11-23 | 2011-05-26 | Schering Corporation | Fused bicyclic pyrimidine derivatives and methods of use thereof |
| US9301929B2 (en) | 2009-11-24 | 2016-04-05 | Merck Sharp & Dohme Corp. | Substituted biaryl derivatives and methods of use thereof |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
| US20210393614A1 (en) * | 2018-10-17 | 2021-12-23 | Duke University | Quinone reductase 2 inhibitors for use as neuroprotective agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| US5276168A (en) * | 1990-06-18 | 1994-01-04 | E. R. Squibb & Sons, Inc. | Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents |
| US5401848A (en) * | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
| KR920014799A (ko) * | 1991-01-18 | 1992-08-25 | 나오가따 다이도 | 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제 |
| US5288725A (en) * | 1992-10-15 | 1994-02-22 | Merck & Co., Inc. | Pyrroloquinoline Bradykinin antagonist |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| AU2157400A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
-
1999
- 1999-09-07 US US09/391,273 patent/US6147090A/en not_active Expired - Fee Related
- 1999-09-08 PA PA19998481501A patent/PA8481501A1/es unknown
- 1999-09-09 HN HN1999000155A patent/HN1999000155A/es unknown
- 1999-09-10 AR ARP990104556A patent/AR021482A1/es active IP Right Grant
- 1999-09-10 DE DE69920727T patent/DE69920727T2/de not_active Expired - Fee Related
- 1999-09-10 DK DK99940421T patent/DK1114033T3/da active
- 1999-09-10 ES ES99940421T patent/ES2228086T3/es not_active Expired - Lifetime
- 1999-09-10 TW TW088115690A patent/TWI232859B/zh not_active IP Right Cessation
- 1999-09-10 JP JP2000574076A patent/JP3655193B2/ja not_active Expired - Fee Related
- 1999-09-10 GT GT199900149A patent/GT199900149A/es unknown
- 1999-09-10 AT AT99940421T patent/ATE277906T1/de not_active IP Right Cessation
- 1999-09-10 AU AU54398/99A patent/AU5439899A/en not_active Abandoned
- 1999-09-10 PT PT99940421T patent/PT1114033E/pt unknown
- 1999-09-10 SV SV1999000149A patent/SV1999000149A/es not_active Application Discontinuation
- 1999-09-10 BR BR9913842-5A patent/BR9913842A/pt not_active Application Discontinuation
- 1999-09-10 PE PE1999000923A patent/PE20001048A1/es not_active Application Discontinuation
- 1999-09-10 EP EP99940421A patent/EP1114033B1/de not_active Expired - Lifetime
- 1999-09-10 MY MYPI99003922A patent/MY121838A/en unknown
- 1999-09-10 SI SI9930672T patent/SI1114033T1/xx unknown
- 1999-09-10 CA CA002344556A patent/CA2344556A1/en not_active Abandoned
- 1999-09-10 CO CO99057639A patent/CO5150220A1/es unknown
- 1999-09-10 WO PCT/IB1999/001529 patent/WO2000017166A1/en not_active Ceased
- 1999-09-13 MA MA25764A patent/MA26687A1/fr unknown
- 1999-09-13 TN TNTNSN99172A patent/TNSN99172A1/fr unknown
- 1999-09-17 DZ DZ990189A patent/DZ2889A1/xx active
-
2000
- 2000-09-27 US US09/671,400 patent/US6395751B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6147090A (en) | 2000-11-14 |
| ES2228086T3 (es) | 2005-04-01 |
| DE69920727D1 (en) | 2004-11-04 |
| HN1999000155A (es) | 2000-01-12 |
| BR9913842A (pt) | 2001-06-12 |
| CA2344556A1 (en) | 2000-03-30 |
| DK1114033T3 (da) | 2004-12-20 |
| MA26687A1 (fr) | 2004-12-20 |
| TWI232859B (en) | 2005-05-21 |
| EP1114033B1 (de) | 2004-09-29 |
| EP1114033A1 (de) | 2001-07-11 |
| MY121838A (en) | 2006-02-28 |
| JP3655193B2 (ja) | 2005-06-02 |
| DZ2889A1 (fr) | 2003-12-15 |
| WO2000017166A1 (en) | 2000-03-30 |
| PA8481501A1 (es) | 2001-12-14 |
| GT199900149A (es) | 2001-03-03 |
| DE69920727T2 (de) | 2006-03-09 |
| SV1999000149A (es) | 2000-07-06 |
| PT1114033E (pt) | 2004-12-31 |
| JP2002526477A (ja) | 2002-08-20 |
| TNSN99172A1 (fr) | 2005-11-10 |
| AR021482A1 (es) | 2002-07-24 |
| SI1114033T1 (en) | 2005-02-28 |
| PE20001048A1 (es) | 2000-10-17 |
| CO5150220A1 (es) | 2002-04-29 |
| AU5439899A (en) | 2000-04-10 |
| US6395751B1 (en) | 2002-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE297898T1 (de) | 4-carboxamino-2-subsitutierte-1,2,3,4- tetrahydrochinoline als cetp inhibitoren | |
| ATE268324T1 (de) | 4-amino substituierte -2-subsituierte-1,2,3,4- tetrahydrochinoline als cetp inhibitoren | |
| PT1114033E (pt) | 4-carboxiamino-2-metil-1,2,3,4-tetra-hidroquinolinas como inibidores de cetp | |
| DE59710982D1 (de) | Cycloalkano-pyridine als CETP-Inhibitoren | |
| ID29241A (id) | Turunan-turunan kinolin teranelasi-1,2 | |
| CU23049A3 (es) | Dihidropirimidinas. | |
| ID28874A (id) | Inhibitor fosfodiesterase 4 turunan ftalazina. | |
| ATE387448T1 (de) | 4,5-pyrazinoxindole als proteinkinasehemmer | |
| ID26909A (id) | Turunan-turunan 1,3,4-oksadiazolon | |
| ATE317396T1 (de) | 14,15-beta-methylen substituierte androgene | |
| DK1149106T3 (da) | 4,5-azolo-oxindoler | |
| EP1156040A4 (de) | 2,4-dioxo-5-arylidenimido-1,3-pyrimidine | |
| ID26368A (id) | Turunan-turunan 2 deoksi higromisin | |
| NO980270L (no) | Trekkanordning | |
| DE60017150D1 (de) | 1,4,5,6 -tetrahydropyrimidine-derivative als vitronectin-hemmer | |
| NO981550D0 (no) | Trekkanordning | |
| ES1039413Y (es) | Nueva ficha-deportista. | |
| ES1040173Y (es) | Nuevo bigudi. | |
| ES1040631Y (es) | Nuevo cepillo-baqueta. | |
| IT1302206B1 (it) | Molletta per il bucato. | |
| ES1040336Y (es) | Lingote mejorado. | |
| ES1041021Y (es) | Antifaz magnetico. | |
| ES1040731Y (es) | Gafa. | |
| ES1040589Y (es) | Expositor-dispensador. | |
| ES1040343Y (es) | Carrito portafregona. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1114033 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |